Long-term (28 days) SLB treatment at a dose of 5.1 mg/kg/day declines the serum AST levels in children with grade 2 hepatotoxicity associated with the maintenance therapy of acute lymphoblastic leukemia.33 Hagag et al34 reported that 1-week silymarin treatment following MTX administration attenuates the MTX-induced hepatotoxicity by reducing the serum AST, ALT, and ALP levels in children with acute lymphoblastic leukemia. This evidence concerns the gene GPT and acute lymphoblastic leukemia.